400 related articles for article (PubMed ID: 22713733)
1. Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions.
Zhao P; Rowland M; Huang SM
Clin Pharmacol Ther; 2012 Jul; 92(1):17-20. PubMed ID: 22713733
[TBL] [Abstract][Full Text] [Related]
2. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.
Zhao P; Zhang L; Grillo JA; Liu Q; Bullock JM; Moon YJ; Song P; Brar SS; Madabushi R; Wu TC; Booth BP; Rahman NA; Reynolds KS; Gil Berglund E; Lesko LJ; Huang SM
Clin Pharmacol Ther; 2011 Feb; 89(2):259-67. PubMed ID: 21191381
[TBL] [Abstract][Full Text] [Related]
3. Physiologically based pharmacokinetic (PBPK) modeling in children.
Barrett JS; Della Casa Alberighi O; Läer S; Meibohm B
Clin Pharmacol Ther; 2012 Jul; 92(1):40-9. PubMed ID: 22669290
[TBL] [Abstract][Full Text] [Related]
4. The role of physiologically based pharmacokinetic modeling in regulatory review.
Huang SM; Rowland M
Clin Pharmacol Ther; 2012 Mar; 91(3):542-9. PubMed ID: 22318616
[TBL] [Abstract][Full Text] [Related]
5. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials.
Leong R; Vieira ML; Zhao P; Mulugeta Y; Lee CS; Huang SM; Burckart GJ
Clin Pharmacol Ther; 2012 May; 91(5):926-31. PubMed ID: 22472993
[TBL] [Abstract][Full Text] [Related]
6. Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.
Rostami-Hodjegan A
Clin Pharmacol Ther; 2012 Jul; 92(1):50-61. PubMed ID: 22644330
[TBL] [Abstract][Full Text] [Related]
7. Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018-2019 Submissions to the US FDA's Office of Clinical Pharmacology.
Zhang X; Yang Y; Grimstein M; Fan J; Grillo JA; Huang SM; Zhu H; Wang Y
J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S160-S178. PubMed ID: 33205429
[TBL] [Abstract][Full Text] [Related]
8. Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration's Office of Clinical Pharmacology.
Grimstein M; Yang Y; Zhang X; Grillo J; Huang SM; Zineh I; Wang Y
J Pharm Sci; 2019 Jan; 108(1):21-25. PubMed ID: 30385284
[TBL] [Abstract][Full Text] [Related]
9. The utility of modeling and simulation in drug development and regulatory review.
Huang SM; Abernethy DR; Wang Y; Zhao P; Zineh I
J Pharm Sci; 2013 Sep; 102(9):2912-23. PubMed ID: 23712632
[TBL] [Abstract][Full Text] [Related]
10. Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization.
Peters SA; Ungell AL; Dolgos H
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):509-18. PubMed ID: 19562647
[TBL] [Abstract][Full Text] [Related]
11. Models of physiology and physiologically based models in clinical pharmacology.
Atkinson AJ; Smith BP
Clin Pharmacol Ther; 2012 Jul; 92(1):3-6. PubMed ID: 22713729
[TBL] [Abstract][Full Text] [Related]
12. The successes and failures of physiologically based pharmacokinetic modeling: there is room for improvement.
Poggesi I; Snoeys J; Van Peer A
Expert Opin Drug Metab Toxicol; 2014 May; 10(5):631-5. PubMed ID: 24517185
[TBL] [Abstract][Full Text] [Related]
13. Perspectives in regulatory science: translational and clinical pharmacology.
Grillo JA; Huang SM
Drug Discov Today Technol; 2016; 21-22():67-73. PubMed ID: 27978990
[TBL] [Abstract][Full Text] [Related]
14. Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.
Shebley M; Sandhu P; Emami Riedmaier A; Jamei M; Narayanan R; Patel A; Peters SA; Reddy VP; Zheng M; de Zwart L; Beneton M; Bouzom F; Chen J; Chen Y; Cleary Y; Collins C; Dickinson GL; Djebli N; Einolf HJ; Gardner I; Huth F; Kazmi F; Khalil F; Lin J; Odinecs A; Patel C; Rong H; Schuck E; Sharma P; Wu SP; Xu Y; Yamazaki S; Yoshida K; Rowland M
Clin Pharmacol Ther; 2018 Jul; 104(1):88-110. PubMed ID: 29315504
[TBL] [Abstract][Full Text] [Related]
15. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
Rossen BR
Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
[TBL] [Abstract][Full Text] [Related]
16. Pharmacometrics at FDA: evolution and impact on decisions.
Powell JR; Gobburu JV
Clin Pharmacol Ther; 2007 Jul; 82(1):97-102. PubMed ID: 17538553
[TBL] [Abstract][Full Text] [Related]
17. Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006.
Bhattaram VA; Bonapace C; Chilukuri DM; Duan JZ; Garnett C; Gobburu JV; Jang SH; Kenna L; Lesko LJ; Madabushi R; Men Y; Powell JR; Qiu W; Ramchandani RP; Tornoe CW; Wang Y; Zheng JJ
Clin Pharmacol Ther; 2007 Feb; 81(2):213-21. PubMed ID: 17259946
[TBL] [Abstract][Full Text] [Related]
18. Supplements and other changes to an approved application. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2004 Apr; 69(68):18727-67. PubMed ID: 15072041
[TBL] [Abstract][Full Text] [Related]
19. Biopharmaceutics Applications of Physiologically Based Pharmacokinetic Absorption Modeling and Simulation in Regulatory Submissions to the U.S. Food and Drug Administration for New Drugs.
Wu F; Shah H; Li M; Duan P; Zhao P; Suarez S; Raines K; Zhao Y; Wang M; Lin HP; Duan J; Yu L; Seo P
AAPS J; 2021 Feb; 23(2):31. PubMed ID: 33619657
[TBL] [Abstract][Full Text] [Related]
20. Clinical pharmacology and the catalysis of regulatory science: opportunities for the advancement of drug development and evaluation.
Zineh I; Woodcock J
Clin Pharmacol Ther; 2013 Jun; 93(6):515-25. PubMed ID: 23571772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
